Impact of SER 109, an Investigational Microbiome Therapeutic on Health-Related Quality of Life in Patients With Recurrent Clostridioides Difficile Infection: Results From ECOSPOR III, a Placebo-Controlled Clinical Trial

被引：0
|
作者：
Brown, Lisa [1 ]
Elizabeth, Hohmann [1 ]
Paul, Feuerstadt [1 ]
Caterina, Oneto [1 ]
Berenson, Charles [1 ]
Christine, Lee [1 ]
Sissi, Pham [1 ]
Ray, Reese Pat [1 ]
Henry, Wu [1 ]
Elaine, Wang [1 ]
Lisa, von Moltke [1 ]
Kevin, Garey [1 ]
机构：
[1] Seres Therapeut, Brooklyn, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2021年 / 46卷 / SUPPL 1期
关键词：
Microbiome; Microbiota-Gut-Brain Axis; Microbiota; Gut-Brain Axis; Fecal Microbiota Transplant;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
P334
引用
收藏
页码：253 / 253
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of SER-109, an investigational microbiome therapeutic for recurrent clostridioides difficile infection: Data from ECOSPOR III, a phase 3 randomized trial.
    Paskovaty, Alla
    Berenson, Charles S.
    Louie, Thomas J.
    Wang, Elaine
    Lombardi, David A.
    von Moltke, Lisa
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] ENGRAFTMENT OF INVESTIGATIONAL MICROBIOME THERAPEUTIC SER-109 IS DURABLE THROUGH 24 WEEKS IN A RANDOMIZED TRIAL (ECOSPOR III) FOR THE TREATMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
    Desjardins, Christopher
    Bryant, Jessica A.
    Walsh, Emily
    Ford, Christopher B.
    Litcofsky, Kevin D.
    Wortman, Jennifer R.
    Henn, Matthew R.
    GASTROENTEROLOGY, 2022, 162 (07) : S651 - S651
  • [3] IMPACT OF SER-109, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC, ON STOOL FATTY ACID METABOLITES IN A PHASE 3 RANDOMIZED TRIAL (ECOSPOR III) FOR TREATMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)
    Bryant, Jessica A.
    Vulic, Marin
    Desjardins, Christopher
    Ford, Christopher B.
    Litcofsky, Kevin D.
    Wortman, Jennifer R.
    Henn, Matthew R.
    GASTROENTEROLOGY, 2022, 162 (07) : S21 - S21
  • [4] SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
    Khanna, Sahil
    Sims, Matthew
    Louie, Thomas J.
    Fischer, Monika
    LaPlante, Kerry
    Allegretti, Jessica
    Hasson, Brooke R.
    Fonte, Allyson T.
    McChalicher, Christopher
    Ege, David S.
    Bryant, Jessica A.
    Straub, Timothy J.
    Ford, Christopher B.
    Henn, Matthew R.
    Wang, Elaine E. L.
    von Moltke, Lisa
    Wilcox, Mark H.
    ANTIBIOTICS-BASEL, 2022, 11 (09):
  • [5] Validation of a Health-Related Quality of Life Questionnaire in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Phase 3 Randomized Trial
    Lapin, Brittany
    Garey, Kevin W.
    Wu, Henry
    Sissi, V
    Huang, Shirley P.
    Reese, Pat Ray
    Wang, Elaine
    Deshpande, Abhishek
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E1195 - E1201
  • [6] 24-WEEK EFFICACY AND SAFETY DATA FROM ECOSPOR-III, A PHASE 3 DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED TRIAL OF SER-109, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC FOR TREATMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
    Korman, Louis
    Lashner, Bret
    Kraft, Colleen
    Sims, Matthew
    Wang, Elaine E.
    Brady, Kelly
    Ford, Christopher B.
    Lombardo, Mary-Jane
    Litcofsky, Kevin D.
    Mahoney, Jennifer C.
    McChalicher, Christopher W.
    Winkler, Jonathan
    Garant, Sarah
    Mcgovern, Babara
    McNullen, Erin
    Henn, Matthew R.
    Trucksis, Michele
    von Moltke, Lisa
    GASTROENTEROLOGY, 2021, 160 (06) : S368 - S369
  • [7] DURABILITY OF THE CLINICAL RESPONSE TO SER-109, AN INVESTIGATIONAL ORAL MICROBIOME THERAPEUTIC, IN A PHASE 3 OPEN-LABEL TRIAL (ECOSPOR IV) IN PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
    Huang, Edward S.
    Lashner, Bret
    Sims, Matthew
    Misra, Bharat
    Tran, Huy
    Korman, Louis
    Khanna, Sahil
    Wang, Elaine E.
    De, Ananya
    Brady, Kelly
    Lombardi, David A.
    Memisolglu, Asli
    McGovern, Barbara H.
    von Moltke, Lisa
    GASTROENTEROLOGY, 2023, 164 (06) : S140 - S140
  • [8] Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109 Secondary Analysis of a Randomized Clinical Trial
    Garey, Kevin W.
    Jo, Jinhee
    Gonzales-Luna, Anne J.
    Lapin, Brittany
    Deshpande, Abhishek
    Wang, Elaine
    Hasson, Brooke
    Pham, Sissi V.
    Huang, Shirley P.
    Reese, Pat Ray
    Wu, Henry
    Hohmann, Elizabeth
    Feuerstadt, Paul
    Oneto, Caterina
    Berenson, Charles S.
    Lee, Christine
    McGovern, Barbara
    vonMoltke, Lisa
    JAMA NETWORK OPEN, 2023, 6 (01) : e2253570
  • [9] VALIDATION OF A HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE IN PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION IN ECOSPOR-III, A PHASE 3 RANDOMIZED TRIAL
    Lapin, B.
    Garey, K.
    Wu, H.
    Pham, S.
    Huang, S.
    Reese, P. R.
    Wang, E.
    McGovern, B.
    Deshpande, A.
    VALUE IN HEALTH, 2022, 25 (07) : S569 - S569
  • [10] SER-109 – eine orale Mikrobiomtherapie für rezidivierende Clostridioides-difficile-InfektionenSER-109 versus Placebo in the Treatment of Adults with Recurrent Clostridium Difficile Infection (ECOSPOR III)SER-109: oral microbiome therapy for recurrent Clostridioides difficile infectionsSER-109 versus Placebo in the Treatment of Adults with Recurrent Clostridium Difficile Infection (ECOSPOR III)
    A. Stallmach
    S. Nitschmann
    Die Innere Medizin, 2022, 63 (7) : 805 - 807
12345